Literature DB >> 16630117

Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro.

Tanyarat Jomgeow1, Yusuke Oji, Naoko Tsuji, Yoko Ikeda, Ken Ito, Asako Tsuda, Tsutomu Nakazawa, Naoya Tatsumi, Nao Sakaguchi, Satoshi Takashima, Toshiaki Shirakata, Sumiyuki Nishida, Naoki Hosen, Manabu Kawakami, Akihiro Tsuboi, Yoshihiro Oka, Kazuyuki Itoh, Haruo Sugiyama.   

Abstract

The wild-type Wilms' tumor gene WT1 is overexpressed in human primary leukemia and in a wide variety of solid cancers. All of the four WT1 isoforms are expressed in primary cancers and each is considered to have a different function. However, the functions of each of the WT1 isoforms in cancer cells remain unclear. The present study demonstrated that constitutive expression of the WT1 17AA(-)/KTS(-) isoform induces morphological changes characterized by a small-sized cell shape in TYK-nu.CP-r (TYK) ovarian cancer cells. In the WT1 17AA(-)/KTS(-) isoform-transduced TYK cells, cell-substratum adhesion was suppressed, and cell migration and in vitro invasion were enhanced compared to that in mock vector-transduced TYK cells. Constitutive expression of the WT1 17AA(-)/KTS(-) isoform also induced morphological changes in five (one gastric, one esophageal, two breast and one fibrosarcoma) of eight cancer cell lines examined. No WT1 isoforms other than the WT1 17AA(-)/KTS(-) isoform induced the phenotypic changes. A decrease in alpha-actinin 1 and cofilin expression and an increase in gelsolin expression were observed in WT1 17AA(-)/KTS(-) isoform-transduced TYK cells. In contrast, co-expression of alpha-actinin 1 and cofilin or knockdown of gelsolin expression by small interfering RNA restored WT1 17AA(-)/KTS(-) isoform-transduced TYK cells to a phenotype that was comparable to that of the parent TYK cells. These results indicated that the WT1 17AA(-)/KTS(-) isoform exerted its oncogenic functions through modulation of cytoskeletal dynamics. The present results may provide a novel insight into the signaling pathway of the WT1 gene for its oncogenic functions. (Cancer Sci 2006; 97: 259-270).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16630117     DOI: 10.1111/j.1349-7006.2006.00169.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  22 in total

Review 1.  Role of the Wilms' tumour transcription factor, Wt1, in blood vessel formation.

Authors:  Holger Scholz; Kay-Dietrich Wagner; Nicole Wagner
Journal:  Pflugers Arch       Date:  2008-12-04       Impact factor: 3.657

2.  Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities.

Authors:  N Tatsumi; N Hojo; O Yamada; M Ogawa; Y Katsura; S Kawata; E Morii; H Sakamoto; R Inaba; A Tsuda; I Fukuda; N Moriguchi; H Hasuwa; M Okabe; F Fujiki; S Nishida; H Nakajima; A Tsuboi; Y Oka; N Hosen; H Sugiyama; Y Oji
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

3.  Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis.

Authors:  Till Plönes; Mitja Fischer; Kerstin Höhne; Hiromi Sato; Joachim Müller-Quernheim; Gernot Zissel
Journal:  Pathol Oncol Res       Date:  2017-01-04       Impact factor: 3.201

Review 4.  Pleural mesothelial cells in pleural and lung diseases.

Authors:  Hitesh Batra; Veena B Antony
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

5.  Identification of mouse helper epitopes for WT1-specific CD4+ T cells.

Authors:  Hiroko Nakajima; Jun Nakata; Kanako Imafuku; Hiromu Hayashibara; Kazuki Isokawa; Keiko Udaka; Fumihiro Fujiki; Soyoko Morimoto; Kana Hasegawa; Naoki Hosen; Yoshiko Hashii; Sumiyuki Nishida; Akihiro Tsuboi; Yoshihiro Oka; Yusuke Oji; Shinji Sogo; Haruo Sugiyama
Journal:  Cancer Immunol Immunother       Date:  2021-07-16       Impact factor: 6.968

6.  Wilms' tumor 1 (Wt1) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in idiopathic pulmonary fibrosis.

Authors:  Suman Karki; Ranu Surolia; Thomas David Hock; Purusotham Guroji; Jason S Zolak; Ryan Duggal; Tong Ye; Victor J Thannickal; Veena B Antony
Journal:  FASEB J       Date:  2013-11-21       Impact factor: 5.191

7.  Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma.

Authors:  Tomoya Kanai; Zensho Ito; Yusuke Oji; Machi Suka; Sumiyuki Nishida; Kazuki Takakura; Mikio Kajihara; Masayuki Saruta; Shuichi Fujioka; Takeyuki Misawa; Tadashi Akiba; Hiroyuki Yanagisawa; Shigetaka Shimodaira; Masato Okamoto; Haruo Sugiyama; Shigeo Koido
Journal:  Oncol Lett       Date:  2018-06-13       Impact factor: 2.967

8.  The Wilms' tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells.

Authors:  Adina Brett; Sony Pandey; Gail Fraizer
Journal:  Mol Cancer       Date:  2013-01-08       Impact factor: 27.401

9.  Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways.

Authors:  R T Sitaram; S Degerman; B Ljungberg; E Andersson; Y Oji; H Sugiyama; G Roos; A Li
Journal:  Br J Cancer       Date:  2010-09-14       Impact factor: 7.640

10.  Wilms' tumor 1 (WT1) promotes ovarian cancer progression by regulating E-cadherin and ERK1/2 signaling.

Authors:  Yun Han; Chao Song; Tingting Zhang; Qianqian Zhou; Xiaoqian Zhang; Jing Wang; Boqun Xu; Xuesen Zhang; Xiaoqiu Liu; Xiaoyan Ying
Journal:  Cell Cycle       Date:  2020-09-07       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.